KR102233229B1 - 다이페닐메탄 유도체의 제조방법 - Google Patents

다이페닐메탄 유도체의 제조방법 Download PDF

Info

Publication number
KR102233229B1
KR102233229B1 KR1020170075799A KR20170075799A KR102233229B1 KR 102233229 B1 KR102233229 B1 KR 102233229B1 KR 1020170075799 A KR1020170075799 A KR 1020170075799A KR 20170075799 A KR20170075799 A KR 20170075799A KR 102233229 B1 KR102233229 B1 KR 102233229B1
Authority
KR
South Korea
Prior art keywords
compound
formula
reaction
mmol
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020170075799A
Other languages
English (en)
Korean (ko)
Other versions
KR20170142904A (ko
Inventor
윤희균
박세환
윤지성
최순규
서희정
박은정
공영규
송광섭
김민주
박소옥
Original Assignee
주식회사 대웅제약
주식회사 녹십자
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102233229(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 주식회사 대웅제약, 주식회사 녹십자 filed Critical 주식회사 대웅제약
Publication of KR20170142904A publication Critical patent/KR20170142904A/ko
Priority to KR1020210036824A priority Critical patent/KR102379584B1/ko
Application granted granted Critical
Publication of KR102233229B1 publication Critical patent/KR102233229B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00—Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020170075799A 2016-06-17 2017-06-15 다이페닐메탄 유도체의 제조방법 Active KR102233229B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020210036824A KR102379584B1 (ko) 2016-06-17 2021-03-22 다이페닐메탄 유도체의 제조방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160075910 2016-06-17
KR1020160075910 2016-06-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020210036824A Division KR102379584B1 (ko) 2016-06-17 2021-03-22 다이페닐메탄 유도체의 제조방법

Publications (2)

Publication Number Publication Date
KR20170142904A KR20170142904A (ko) 2017-12-28
KR102233229B1 true KR102233229B1 (ko) 2021-03-29

Family

ID=60664449

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020170075799A Active KR102233229B1 (ko) 2016-06-17 2017-06-15 다이페닐메탄 유도체의 제조방법
KR1020210036824A Active KR102379584B1 (ko) 2016-06-17 2021-03-22 다이페닐메탄 유도체의 제조방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020210036824A Active KR102379584B1 (ko) 2016-06-17 2021-03-22 다이페닐메탄 유도체의 제조방법

Country Status (29)

Country Link
US (2) US10640496B2 (enExample)
EP (2) EP3663292B1 (enExample)
JP (4) JP6763978B2 (enExample)
KR (2) KR102233229B1 (enExample)
CN (2) CN113651803B (enExample)
AU (1) AU2017285813B2 (enExample)
CA (2) CA3026756C (enExample)
CL (1) CL2018003645A1 (enExample)
CO (1) CO2018014018A2 (enExample)
DK (2) DK3663292T3 (enExample)
DO (1) DOP2018000287A (enExample)
EC (1) ECSP19000185A (enExample)
ES (2) ES2891825T3 (enExample)
HR (1) HRP20211670T8 (enExample)
HU (1) HUE056428T2 (enExample)
MA (2) MA50774B1 (enExample)
MX (2) MX392177B (enExample)
MY (1) MY203941A (enExample)
NZ (1) NZ749398A (enExample)
PE (2) PE20190467A1 (enExample)
PH (1) PH12018550206A1 (enExample)
PL (2) PL3473621T3 (enExample)
PT (2) PT3473621T (enExample)
RS (1) RS62550B1 (enExample)
SA (2) SA521422474B1 (enExample)
SG (2) SG11201811154QA (enExample)
SI (1) SI3663292T1 (enExample)
TN (1) TN2018000437A1 (enExample)
WO (1) WO2017217792A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011054773A1 (de) 2011-10-25 2013-04-25 Vb Autobatterie Gmbh & Co. Kgaa Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols
PE20211206A1 (es) * 2018-08-13 2021-07-05 Dae Woong Pharma Preparacion de intermedio util para la sintesis de inhibidor de sglt
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
WO2021172955A1 (ko) * 2020-02-27 2021-09-02 주식회사 대웅제약 Sglt 저해제의 합성에 유용한 중간체 및 이를 이용한 sglt 저해제의 제조 방법
US12448360B2 (en) * 2020-09-10 2025-10-21 Daewoong Pharmaceutical Co., Ltd. Synthesis method for preparing SGLT inhibitor intermediate
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
CN113200860B (zh) * 2021-04-29 2024-07-30 爱斯特（成都）生物制药股份有限公司 一种sglt2抑制剂中间体的制备方法
KR20230046784A (ko) * 2021-09-30 2023-04-06 주식회사 대웅제약 이나보글리플로진을 포함하는 약학 조성물
CN113801010A (zh) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 一种5-溴-2-氯苯甲酸的制备方法
CN113912487B (zh) * 2021-11-23 2024-05-28 山东研峰新材料科技有限公司 一种2,5-双卤代苯甲酸的合成方法
KR20230110001A (ko) * 2022-01-14 2023-07-21 주식회사 대웅제약 Ssglt 저해제의 합성에 유용한 중간체의 제조 방법
KR20240044190A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법
KR20240044194A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정
CN119968202A (zh) 2022-09-29 2025-05-09 株式会社大熊制药 用于预防或治疗心血管衰老疾病的包含依那格列净的药物组合物
KR20240047952A (ko) 2022-10-05 2024-04-12 주식회사 대웅제약 이나보글리플로진을 포함하는 신장애 및/또는 당뇨병 예방 또는 치료용 약학 조성물
EP4631498A1 (en) 2022-12-21 2025-10-15 Daewoong Therapeutics Inc. Eye drop-type pharmaceutical composition containing envogliflozin
KR20240107660A (ko) 2022-12-30 2024-07-09 주식회사 대웅제약 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물
KR102853437B1 (ko) * 2024-11-13 2025-09-04 대웅바이오(주) 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837948B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) 분배 투입법을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837941B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) Inline quenching 공정을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529477A (ja) 2008-07-30 2011-12-08 フエルレル インターナショナル，ソシエダッド アノニマ １，６−ジヒドロ−２ｈ−３−オキサ−６−アザ−ａｓ−インダセン化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
EP2514756B1 (en) * 2003-08-01 2014-12-17 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
WO2009014970A1 (en) 2007-07-26 2009-01-29 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
KR101576589B1 (ko) * 2011-06-01 2015-12-10 주식회사 녹십자 Sglt2 억제제로서의 신규한 다이페닐메탄 유도체
US9340521B2 (en) 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529477A (ja) 2008-07-30 2011-12-08 フエルレル インターナショナル，ソシエダッド アノニマ １，６−ジヒドロ−２ｈ−３−オキサ−６−アザ−ａｓ−インダセン化合物

Also Published As

Publication number Publication date
PE20190467A1 (es) 2019-04-04
KR20170142904A (ko) 2017-12-28
CN113651803A (zh) 2021-11-16
MX2021008988A (es) 2022-05-05
US20190382390A1 (en) 2019-12-19
SG10201911782RA (en) 2020-02-27
EP3663292B1 (en) 2021-09-01
US10889574B2 (en) 2021-01-12
PT3473621T (pt) 2021-10-04
ES2898336T3 (es) 2022-03-07
SA518400666B1 (ar) 2021-11-30
JP2021152054A (ja) 2021-09-30
JP6763978B2 (ja) 2020-09-30
CN113651803B (zh) 2022-10-28
EP3473621B1 (en) 2021-08-04
PT3663292T (pt) 2021-11-08
HUE056428T2 (hu) 2022-02-28
DK3473621T3 (da) 2021-09-06
US20190169174A1 (en) 2019-06-06
CO2018014018A2 (es) 2019-03-08
RU2021129636A (ru) 2021-11-22
AU2017285813A1 (en) 2019-01-17
HRP20211670T8 (hr) 2022-03-18
EP3473621A4 (en) 2020-03-11
NZ749398A (en) 2020-01-31
KR20210036892A (ko) 2021-04-05
WO2017217792A1 (ko) 2017-12-21
PL3473621T3 (pl) 2022-01-10
PH12018550206A1 (en) 2019-09-30
MX2018015647A (es) 2019-04-11
ES2891825T3 (es) 2022-01-31
MA44545B2 (fr) 2020-11-30
JP7669206B2 (ja) 2025-04-28
EP3663292A1 (en) 2020-06-10
JP7773506B2 (ja) 2025-11-19
MY203941A (en) 2024-07-25
PE20240590A1 (es) 2024-03-21
CN109311861B (zh) 2021-08-24
JP2020117528A (ja) 2020-08-06
JP2019521985A (ja) 2019-08-08
CA3081033C (en) 2022-04-12
SG11201811154QA (en) 2019-01-30
BR112018076243A2 (pt) 2019-03-26
MA44545B1 (fr) 2020-05-29
TN2018000437A1 (en) 2020-06-15
MA44545A1 (fr) 2019-10-31
AU2017285813B2 (en) 2020-02-06
ECSP19000185A (es) 2019-01-31
CA3026756C (en) 2021-03-02
KR102379584B1 (ko) 2022-03-29
DK3663292T3 (da) 2021-10-25
CN109311861A (zh) 2019-02-05
DOP2018000287A (es) 2019-03-31
EP3473621A1 (en) 2019-04-24
MX392177B (es) 2025-03-19
RU2019101056A (ru) 2020-07-17
CA3026756A1 (en) 2017-12-21
JP7352509B2 (ja) 2023-09-28
SA521422474B1 (ar) 2023-11-02
HRP20211670T1 (hr) 2022-02-18
CL2018003645A1 (es) 2019-03-22
RS62550B1 (sr) 2021-12-31
PL3663292T3 (pl) 2022-01-17
RU2019101056A3 (enExample) 2020-07-17
MA50774A1 (fr) 2021-03-31
SI3663292T1 (sl) 2022-01-31
MX385640B (es) 2025-03-18
MA50774B1 (fr) 2022-02-28
CA3081033A1 (en) 2017-12-21
JP2023145481A (ja) 2023-10-11
US10640496B2 (en) 2020-05-05

Similar Documents

Publication Publication Date Title
KR102379584B1 (ko) 다이페닐메탄 유도체의 제조방법
EP4112612B1 (en) Intermediate useful for synthesis of sglt inhibitor and method for preparing sglt inhibitor using same
RU2814846C1 (ru) Способ получения производного дифенилметана
RU2797392C2 (ru) Способ получения производного дифенилметана
RU2774998C2 (ru) Способ получения производного дифенилметана
HK40057423B (en) Method for producing diphenylmethane derivative
HK40057423A (en) Method for producing diphenylmethane derivative
HK40002293A (en) Method for producing diphenylmethane derivative
WO2018029264A1 (en) Process for preparation of dapagliflozin and intermediates thereof
HK40002293B (zh) 用於制备二苯基甲烷衍生物的方法
BR112018076243B1 (pt) Método para produzir um composto derivado de difenil metano e forma cristalina do composto produzido pelo dito método
US12497390B2 (en) Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using same
RU2802443C1 (ru) Промежуточное соединение, применяемое для синтеза ингибитора sglt, и способ получения ингибитора sglt с применением указанного промежуточного соединения

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20170615

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191112

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20170615

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210104

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210303

PA0107 Divisional application

Comment text: Divisional Application of Patent

Patent event date: 20210322

Patent event code: PA01071R01D

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210323

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210324

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20230227

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

PR1001 Payment of annual fee

Payment date: 20230314

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240327

Start annual number: 5

End annual number: 5